The world’s most prescribed COPD dry powder inhaler
Boehringer Ingelheim
Handihaler
Used in combination with the medication Spiriva, is used to treat chronic obstructive pulmonary disease (COPD), bringing relief to millions of patients around the world for over 20 years.
The Challenge
Supporting Boehringer Ingelheim in reducing the unit cost and increasing usability of the device
Boehringer Ingelheim wanted usability improvements to their existing dry powder inhaler and a solution for high manufacturing costs. We took on the challenge to design a new inhaler that retained functional performance, was easy to use and that was cheaper to produce.
The Solution
Retaining the cost functional inhaler principles, we improved usability and created a unique visual identity. We also reduced the component count, achieving an overall production cost reduction of 60%.
The Execution
Our teams worked throughout the project lifecycle, including the research, development, prototyping, production specification and manufacture of 10,000 units – always ensuring the inhaler continued to deliver uncompromised technical performance.
The Impact
The device behind a 20-year pharmaceutical blockbuster
Launched in 2004, the Handihaler became the world’s most prescribed COPD product within two years of launch and continues to be used, globally, over 20 years later.
Speak to our experts about your unique challenge
Whether you’re identifying your next innovation priority, or looking to accelerate development of an existing concept, our team will have advice to help you move forward.
Related projects
We’ve brought over 150 products to life, pioneering progress in pharma and life-saving medtech.
